Getting to the bottom of the cause in this 29-year-old woman illustrates the diagnostic co ...

Results from the CHOICE-2 trial show a 15% absolute increase in excellent functional outcomes with intra-arterial alteplase ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

NEW ORLEANS -- Loberamisal improved functional outcomes after acute ischemic stroke in a placebo-controlled phase III trial, ...

With the study adding to a mix of conflicting trial results, it’s not yet time to update guidelines, Shyam Prabhakaran says.

Women who regularly follow a Mediterranean diet show a lower risk of stroke, according to a new study. View on euronews ...

An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic ...

Asundexian cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.

As stroke systems of care evolve, clinicians are increasingly torn between the known safety of traditional, aggressive ...